Overview

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

Status:
Not yet recruiting

Trial end date:
2022-07-30

Target enrollment:

Participant gender:

Summary

Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy. Hormonal therapy typically consists of oral estradiol and spironolactone, which induce drug-metabolizing enzymes after prolonged administration. This study evaluates the bi-directional potential drug interaction between the antiretroviral drug, doravirine, when co-administered with estradiol and spironolactone.

Phase:

Phase 1

Details

Lead Sponsor:

Thomas Jefferson University

Treatments:

Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Lamivudine
Polyestradiol phosphate
Spironolactone
Tenofovir